● Recruiting

A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia

Condition: Non-familial Hypercholesterolemia and Mixed Hyperlipidemia · Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

PhasePhase 3

Planned participants760

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the efficacy and safety of SYH2053 monotherapy in patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia . This trial plans to enroll 760 Participants.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Information Group officer · 0311-69085587 · ctr-contact@cspc.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Affiliation: Peking University Third Hospital	Beijing, Beijing Municipality, China	Not Yet Recruiting
Affiliation: Peking University Third Hospital	Beijing, Beijing Municipality, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07421297